Media headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioverativ earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.7929013126662 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several equities research analysts have commented on the stock. William Blair reaffirmed a “hold” rating on shares of Bioverativ in a report on Thursday, March 8th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Bioverativ in a report on Wednesday, January 24th. Argus reaffirmed a “hold” rating on shares of Bioverativ in a report on Wednesday, January 24th. Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the company a “hold” rating in a report on Monday, November 20th. Finally, Piper Jaffray Companies downgraded shares of Bioverativ from an “overweight” rating to a “neutral” rating in a report on Monday, January 22nd. Twelve investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $63.83.

How to Become a New Pot Stock Millionaire

Shares of BIVV stock remained flat at $$104.98 during trading on Friday. Bioverativ has a 12-month low of $48.14 and a 12-month high of $105.01. The stock has a market capitalization of $11,360.00 and a PE ratio of 38.31.

Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. The firm had revenue of $328.70 million for the quarter, compared to the consensus estimate of $325.89 million. research analysts predict that Bioverativ will post 3.82 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/bioverativ-bivv-given-media-sentiment-score-of-0-22/1944074.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Insider Buying and Selling by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.